Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cardiff Oncology Inc CRDF

Healthcare Biotechnology
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal... see more

Recent & Breaking News (NDAQ:CRDF)

Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative

PR Newswire November 18, 2021

Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor Conferences

PR Newswire November 9, 2021

Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates

PR Newswire November 4, 2021

Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

PR Newswire September 8, 2021

Cardiff Oncology to Present at Upcoming Investor Conferences in September

PR Newswire September 7, 2021

Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021

PR Newswire August 25, 2021

Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates

PR Newswire August 5, 2021

Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer

PR Newswire July 12, 2021

Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021

PR Newswire July 6, 2021

Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes

PR Newswire June 28, 2021

Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors

PR Newswire June 10, 2021

Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer

PR Newswire June 8, 2021

Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference

PR Newswire May 20, 2021

Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights

PR Newswire May 6, 2021

Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC

PR Newswire April 12, 2021

Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC

PR Newswire April 10, 2021

Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC

PR Newswire April 10, 2021

Cardiff Oncology to Host Key Opinion Leader Webinar on Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer

PR Newswire April 8, 2021

Cardiff Oncology to Present at the Oppenheimer 31st Annual Healthcare Conference

PR Newswire March 11, 2021

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021

PR Newswire March 10, 2021